Search results
36 results
- NewsNEWS Homepage News News On this page find all the latest news, events and activities that involves Dr. Falk Pharma. Filter news All categories Corporate Press release Study Indication Event
- Terms & conditions of useLegal notices Homepage Terms & conditions of use Terms and Conditions of Use General Conditions of Use When you use this website, you are agreeing to the following conditions. This website has been…
- NEWSROOMPrometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD AntibodySAN DIEGO and FREIBURG, Germany, Aug. 13, 2020 /PRNewswire/ — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of…
- NEWSROOMRenexxion Ireland Ltd. & Dr. Falk Pharma GmbH announce a Licensing and Collaboration AgreementRenexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal (“GI”) disorders, announced today that it has…
- NEWSROOMDr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac DiseaseDr. Falk Pharma GmbH and Zedira announce start of the phase 2b clinical trial of ZED1227, a direct-acting and specific inhibitor of tissue transglutaminase, in patients with Celiac Disease.
- NEWSROOMAdults with EOE market research surveyDr. Falk Pharma would like to thank all responders to our survey on Adults with EoE.
- NEWSROOMTGA regulatory approval for Jorveza 0.5mg orally disintegrating tabletsDr. Falk Pharma Australia is pleased to announce we have received TGA regulatory approval for Jorveza<sup>®</sup> 0.5mg orally disintegrating budesonide tablet - indicated "for the treatment of…